

PRODUCT  
CANDIDATE:  
**MOB-015**

**\$88M**

**Annual Canadian market  
for Onychomycosis**

Current Market has only one  
main product player

**Significant opportunity for  
market disruption**

Sources:  
IQVIA CompuScript Sep 2023 MAT

**cipher**<sup>TM</sup>  
PHARMACEUTICALS

Acquired marketing  
rights from:

Moberg Pharma AB (OMX:MOB)



Indication:

Onychomycosis (Nail fungus)

Advantage:

Topical application, improved safety profile, once weekly  
treatment

Regulatory next step:

EU: Product approved, July 2023  
US: Pivotal Phase III study underway, enrollment completed

Timeline:

US: Pivotal Phase III study results expected January 2025